The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic electroluminescent device having improved operating voltage, luminous efficiency, lifetime, and/or power efficiency.

Turbinmicin, an isolated compound of Formula (I) or IA is provided. Turbinomycin compounds of Formula (II) or (IIA) are also provided. A compound isolated from a bacterial species from the sea squirt, Ecteinascidia turbinate, and having a chemical formula of C.sub.34H.sub.29NO.sub.11 is also provided. Compositions including turbinmicin and turbinmicin compounds, such as pharmaceutical compositions including effective amounts of turbinmicin or turbinomicing compounds for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with turbinmicin, turbinmicin compounds and compositions thereof are disclosed.

Turbinmicin, an isolated compound of Formula (I) or IA is provided. Turbinomycin compounds of Formula (II) or (IIA) are also provided. A compound isolated from a bacterial species from the sea squirt, Ecteinascidia turbinate, and having a chemical formula of C.sub.34H.sub.29NO.sub.11 is also provided. Compositions including turbinmicin and turbinmicin compounds, such as pharmaceutical compositions including effective amounts of turbinmicin or turbinomicing compounds for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with turbinmicin, turbinmicin compounds and compositions thereof are disclosed.

A compound represented by the following formula (1), wherein X.sub.1 is O or S, and two or more of Y.sub.1, Y.sub.2 and Y.sub.3 are N, provided that the case where one or both of —Ar.sub.1-Ar.sub.2 and —Ar.sub.3-Ar.sub.4 is a p-terphenyl-3-yl group is excluded. ##STR00001##

The present disclosure provides NIR- and SWIR-active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.

The present disclosure provides NIR- and SWIR-active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.

The subject invention pertains to compositions comprising albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo. The subject invention further pertains to methods of treating a subject with HIV using albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo.

The subject invention pertains to compositions comprising albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo. The subject invention further pertains to methods of treating a subject with HIV using albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

##STR00001##

For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

##STR00001##

For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.